Advertisement Invitrogen signs agreement with Brendan for assay analysis software - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Invitrogen signs agreement with Brendan for assay analysis software

Invitrogen has entered into an exclusive agreement with Brendan Technologies to customize its StatLIA assay analysis software to facilitate the analysis of protein samples.

Brendan’s StatLIA software allows researchers to quantitate proteins with measurable accuracy and improve assay performance through automated quality control. StatLIA also helps researchers troubleshoot sample preparation problems using advanced adaptive learning processes.

According to the company, the StatLIA software also improves the drug/biomarker discovery, validation and development process with reduced timelines and costs. It will also allow researchers to make better informed judgments about the compatibility of separate data sets.

The software will be designed to work with protein quantitation through mass spectrometry, which is an advanced scientific technique used to analyze compounds based on their molecular composition.

Kip Miller, Invitrogen’s senior vice president of BioDiscovery, said: “This software maximizes the value of our reagents through state-of-the-art computations and analysis of proteomics mass spectrometry.”